Genomic impact of transient low-dose decitabine treatment on primary AML cells

Acute myeloid leukemia (AML) is characterized by dysregulated gene expression and abnormal patterns of DNA methylation; the relationship between these events is unclear. Many AML patients are now being treated with hypomethylating agents, such as decitabine (DAC), although the mechanisms by which it...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Blood Ročník 121; číslo 9; s. 1633
Hlavní autoři:	Klco, Jeffery M, Spencer, David H, Lamprecht, Tamara L, Sarkaria, Shawn M, Wylie, Todd, Magrini, Vincent, Hundal, Jasreet, Walker, Jason, Varghese, Nobish, Erdmann-Gilmore, Petra, Lichti, Cheryl F, Meyer, Matthew R, Townsend, R Reid, Wilson, Richard K, Mardis, Elaine R, Ley, Timothy J
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 28.02.2013
Témata:	Animals Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - pharmacology Azacitidine - administration & dosage Azacitidine - analogs & derivatives Azacitidine - pharmacology Cells, Cultured CpG Islands - drug effects CpG Islands - genetics Decitabine DNA Methylation - drug effects DNA Methylation - genetics Dose-Response Relationship, Drug Gene Expression Profiling Gene Expression Regulation, Leukemic - drug effects Genome, Human - drug effects Humans Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology Mice Microarray Analysis Primary Cell Culture Time Factors
ISSN:	1528-0020, 1528-0020
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!